secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024184
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen reports Q3 net loss of $18.6M; cash $195.8M; Phase 1 PGN-EDO51 data positive
--------------------------------------------------------------------------------

- Net loss widened to $18.6M (vs $8.1M in Q3 2021); R&D expenses $16.0M; G&A $3.6M.
- Cash and equivalents $195.8M as of Sep 30, 2022; ~23.6M shares outstanding.
- Phase 1 HNV trial of PGN-EDO51 met primary endpoint; highest exon skipping vs competitors.
- PGN-EDO51 Phase 2a in DMD patients and PGN-EDODM1 Phase 1/2 both expected H1 2023.
- Appointed Habib Dable (former Acceleron CEO) to Board; pipeline milestones by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017022024184/0000950170-22-024184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017022024184/pepg-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer